Could Routine Brain Scans Change Care for Late-Stage Breast Cancer Patients?
Key Takeaways:
• A phase 3 trial in progress is testing whether routine brain MRIs could improve outcomes for stage 4 breast cancer patients
• The study will compare six-month MRI surveillance and current guidelines that don’t recommend scans without symptoms
• Phase 2 findings showed about 25% of patients in each subtype developed brain metastases by the second MRI
Patients with stage 4 breast cancer are not recommended to have routine screening for brain metastases if asymptomatic under current clinical guidelines.
However, new findings from Moffitt Cancer Center researchers presented at the 2026 American Society of Clinical Oncology Annual Meeting suggest those National Comprehensive Cancer Network guidelines may warrant reconsideration.
A phase 3 trial in progress that builds on phase 2 findings began this year and aims to better understand the benefits and potential drawbacks of earlier brain surveillance.
“We’re really trying to understand what the benefits are of early brain surveillance and metastasis intervention as well as the potential disadvantages and determine if a change to current guidelines is warranted,” said Kamran Ahmed, MD, a breast radiation oncologist at Moffitt and principal investigator of the trial.
The hope? To improve patient outcomes, preserve quality of life and potentially save lives.
Investigating Benefits and Drawbacks
The trial in progress, now in phase 3, will enroll 156 patients with triple-negative, HER2-positive, hormone receptor-positive and HER2-negative breast cancers.
The patients are broken up into two groups.
One will receive MRIs every six months for two years, while the other will undergo a baseline MRI with continued follow-up per current guidelines, meaning no additional brain MRIs will take place unless there are suspicious symptoms.
Such symptoms could include headaches, issues with balance and coordination, seizures, or dizziness.
“Hopefully we’ll learn more about the quality-of-life benefits and drawbacks from surveillance brain MRIs and the potential for earlier access to therapies for metastasis,” Ahmed said.
Building on the Phase 2 Trial
Researchers are enrolling patients within 60 days of their stage 4 diagnosis or starting first-line therapy in the phase 3 trial. That’s much earlier compared to the previous phase 2 study.
This trial will more closely examine patients’ quality of life. Researchers will also analyze blood and tissue samples to better understand which patients may be at higher risk for brain metastases and could benefit most from surveillance.
After the second MRI in the phase 2 study, the number of patients with brain metastasis was about 25% in each subtype. Following diagnosis, patients went on to receive early treatment for their brain metastases, including changes in systemic therapy and local therapies.
Funding support for the phase 3 trial was granted by the Florida Department of Health and the Bankhead Coley Cancer Research Foundation.
To learn more about the phase 2 study, you can watch the feature on PBS here.
